No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants

Lucio Caccamo, Raffaella Romeo, Giorgio Rossi, Mauro Maggioni, Ferdinando Radice, Giovanna Lunghi, Massimo Colombo, Luigi R. Fassati

Research output: Contribution to journalArticlepeer-review


Recurrence of hepatitis B impairs the outcome of liver transplantation (OLT). In serum hepatitis B virus (HBV)-DNA-positive recipients, prophylaxis using lamivudine and immunoglobulins (HBIg) reduces the risk of recurrence, but it is undefined whether this regimen also protects candidates with YMDD mutants. Seventeen OLT viraemic candidates received pre-emptive lamivudine followed by post-OLT prophylaxis with lamivudine and HBIg. Both sera and liver biopsies were prospectively collected and high-sensitive polymerase chain reaction (PCR) assay was applied for HBV-DNA detection. Finally, the presence of YMDD mutants was explored in all PCR-positive samples. All patients remained hepatitis B recurrence-free after a mean follow up of 32 months. By PCR, serum HBV-DNA was detectable in 64.3% of cases at OLT-baseline, in 64.7% under combined prophylaxis and in 58.8% in patients (70.5% of the total) with a minimum follow up of 24 months. At OLT-baseline, YMDD mutants were found in 44.4% of patients. After OLT, mutants were present in 50% of patients but only in 16.6% of cases in the long period. Although 41% of the native livers and 42.8% of the analysed grafts harboured HBV-DNA, YMDD mutants were detected in 57% of the native positive livers. YMDD mutants were largely detected both at OLT-baseline and post-OLT, but their presence decreased over time. Regardless of the presence of YMDD mutants, no hepatitis B recurrence was observed in our OLT recipients using preemptive lamivudine followed by continuous prophylaxis with lamivudine and HBIg.

Original languageEnglish
Pages (from-to)186-192
Number of pages7
JournalTransplant International
Issue number2
Publication statusPublished - Feb 2005


  • Anti-hepatitis B virus immunoglobulins
  • Hepatitis B virus
  • Lamivudine
  • Liver transplantation
  • Polymerase chain reaction

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants'. Together they form a unique fingerprint.

Cite this